EyePoint Pharmaceuticals Inc (EYPT)
8.35
-0.60
(-6.76%)
USD |
NASDAQ |
Nov 21, 16:00
8.345
0.00 (0.00%)
After-Hours: 20:00
EyePoint Pharmaceuticals Enterprise Value: 316.10M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 316.10M |
| November 20, 2024 | 357.39M |
| November 19, 2024 | 374.80M |
| November 18, 2024 | 331.80M |
| November 15, 2024 | 372.07M |
| November 14, 2024 | 462.16M |
| November 13, 2024 | 480.59M |
| November 12, 2024 | 504.48M |
| November 11, 2024 | 565.22M |
| November 08, 2024 | 539.97M |
| November 07, 2024 | 537.24M |
| November 06, 2024 | 570.68M |
| November 05, 2024 | 538.60M |
| November 04, 2024 | 544.74M |
| November 01, 2024 | 569.31M |
| October 31, 2024 | 548.84M |
| October 30, 2024 | 359.60M |
| October 29, 2024 | 363.88M |
| October 28, 2024 | 394.92M |
| October 25, 2024 | 254.69M |
| October 24, 2024 | 257.90M |
| October 23, 2024 | 279.31M |
| October 22, 2024 | 321.59M |
| October 21, 2024 | 318.92M |
| October 18, 2024 | 337.65M |
| Date | Value |
|---|---|
| October 17, 2024 | 343.00M |
| October 16, 2024 | 349.96M |
| October 15, 2024 | 275.03M |
| October 14, 2024 | 290.55M |
| October 11, 2024 | 218.83M |
| October 10, 2024 | 187.25M |
| October 09, 2024 | 195.28M |
| October 08, 2024 | 200.09M |
| October 07, 2024 | 212.40M |
| October 04, 2024 | 208.12M |
| October 03, 2024 | 194.21M |
| October 02, 2024 | 185.64M |
| October 01, 2024 | 174.40M |
| September 30, 2024 | 173.87M |
| September 27, 2024 | 146.83M |
| September 26, 2024 | 151.64M |
| September 25, 2024 | 155.93M |
| September 24, 2024 | 166.09M |
| September 23, 2024 | 163.42M |
| September 20, 2024 | 196.60M |
| September 19, 2024 | 211.05M |
| September 18, 2024 | 196.60M |
| September 17, 2024 | 189.64M |
| September 16, 2024 | 192.85M |
| September 13, 2024 | 206.77M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-36.76M
Minimum
Dec 19 2022
1.126B
Maximum
Feb 12 2024
228.20M
Average
173.16M
Median
Jun 24 2021
Enterprise Value Benchmarks
| Cassava Sciences Inc | 1.399B |
| Regeneron Pharmaceuticals Inc | 74.00B |
| Adverum Biotechnologies Inc | -33.63M |
| Regenxbio Inc | 199.36M |
| Editas Medicine Inc | -69.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -29.36M |
| Revenue (Quarterly) | 10.52M |
| Total Expenses (Quarterly) | 43.27M |
| EPS Diluted (Quarterly) | -0.54 |
| Gross Profit Margin (Quarterly) | 93.01% |
| Profit Margin (Quarterly) | -279.0% |
| Earnings Yield | -23.83% |
| Normalized Earnings Yield | -23.83 |